Galectin Therapeutics Ownership
| GALT Stock | USD 1.59 0.06 3.92% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 62 M | Current Value 62 M | Avarage Shares Outstanding 34.3 M | Quarterly Volatility 19.8 M |
Galectin |
Galectin Stock Ownership Analysis
About 31.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.73. Galectin Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 23rd of March 2012. Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Galectin Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. To learn more about Galectin Therapeutics call Joel CPA at 678 620 3186 or check out https://galectintherapeutics.com.Besides selling stocks to institutional investors, Galectin Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Galectin Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Galectin Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Galectin Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 31.0% of Galectin Therapeutics are currently held by insiders. Unlike Galectin Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Galectin Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Galectin Therapeutics' insider trades
Galectin Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Galectin Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Galectin Therapeutics backward and forwards among themselves. Galectin Therapeutics' institutional investor refers to the entity that pools money to purchase Galectin Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Retirement Guys Formula Llc | 2024-12-31 | 155.3 K | Soltis Investment Advisors, Llc | 2024-12-31 | 140.8 K | Lpl Financial Corp | 2024-12-31 | 138.9 K | Commonwealth Equity Services Inc | 2024-12-31 | 134.5 K | Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 118.6 K | Cutter & Co Brokerage, Inc. | 2024-12-31 | 115.5 K | Charles Schwab Investment Management Inc | 2024-12-31 | 65.1 K | Jpmorgan Chase & Co | 2024-12-31 | 59.7 K | Sanctuary Advisors, Llc | 2024-12-31 | 58.4 K | Vanguard Group Inc | 2024-12-31 | 2.1 M | Blackrock Inc | 2024-12-31 | 1.7 M |
Galectin Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Galectin Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Galectin Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Galectin Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Galectin Therapeutics Outstanding Bonds
Galectin Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Galectin Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Galectin bonds can be classified according to their maturity, which is the date when Galectin Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ADGLXY 2625 31 MAR 36 Corp BondUS36321PAB67 | View | |
| ADGLXY 175 30 SEP 27 Corp BondUS36321PAA84 | View | |
| ADGLXY 216 31 MAR 34 Corp BondUS36321PAD24 | View | |
| ADGLXY 294 30 SEP 40 Corp BondUS36321PAE07 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.